Arginine vasopressin in advanced cardiovascular failure during the post-resuscitation phase after cardiac arrest

Summary Arginine vasopressin (AVP) has been employed successfully during cardiopulmonary resuscitation, but there exist only few data about the effects of AVP infusion for cardiovascular failure during the post-cardiac arrest period. Cardiovascular failure is one of the main causes of death after successful resuscitation from cardiac arrest. Although the “post-resuscitation syndrome” has been described as a “sepsis-like” syndrome, there is little information about the haemodynamic response to AVP in advanced cardiovascular failure after cardiac arrest. In this retrospective study, haemodynamic and laboratory variables in 23 patients with cardiovascular failure unresponsive to standard haemodynamic therapy during the post-cardiac arrest period were obtained before, and 30 min, 1, 4, 12, 24, 48, and 72 h after initiation of a supplementary AVP infusion (4 IU/h). During the observation period, AVP significantly increased mean arterial blood pressure (58 ± 14 to 75 ± 19 mmHg, p p  = 0.03), adrenaline (epinephrine) (0.58 ± 0.23 to 0.04 ± 0.03 μg/kg/min, p  = 0.001), and milrinone requirements (0.46 ± 0.15 to 0.33 ± 0.22 μg/kg/min, p p p p p  = 0.001) increased after AVP. There were no differences in the haemodynamic or laboratory response to AVP between survivors and non-survivors. In this study, advanced cardiovascular failure that was unresponsive to standard therapy could be reversed successfully with supplementary AVP infusion in >90% of patients surviving cardiac arrest.